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Available online 1 July 2016Objective: To determine the effect of vitamin E in reducing cardiovascular mortality in diabetic patients.
Data source: Review of several English language primary studies published from 2004 to 2015.
Outcome measured: The primary outcomes measure by all studies included 30-day mortality due to congestive
heart failure, myocardial infarction, stroke, and HDL function as it relates to cardiovascular outcomes. The sec-
ondary outcomes included hospitalization for CHF and coronary revascularization.
Results: Five Randomized, double-blind, placebo-controlled trials and 11 studies were used for this review. The
study published by Jaxa-Chamiec et al. showed that vitamin E is beneﬁcial along with vitamin C but is not effec-
tive when used alone. The study facilitated byMarchioli et al., showed that vitamin E supplementation is associ-
ated with a statistically non-signiﬁcant (p = 0.18) increased risk of developing CHF. Finally, a study by Milman
et al. showed that vitamin E supplementation is beneﬁcial compared with a placebo group. This was a recurring
theme and common ﬁnding among the studies explored within the context of this review.
Conclusions: Although, two studies showed no beneﬁt from vitamin E supplementation, the remaining studies
demonstrated that vitamin E supplementation provided cardiovascular beneﬁts in a speciﬁc diabetic subpopula-
tion. The study population that derived a favorable outcome fromvitaminE supplementation consisted of diabet-
ic patients with the Hp 2–2 genotype. Hence, further studies should be conducted in diabetic populations with
the Hp 2–2 genotype for identifying the deﬁnitive effects of vitamin E.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Prophylaxis1. Introduction
Cardiovascular disease is amajor cause ofmorbidity andmortality in
patients with type 2 diabetes mellitus (T2DM). In 2004, death due to
cardiovascular complication in the diabetic population aged 65 years
or older was around 68% [1]. Clearly, there is an urgent need for inter-
ventions that can reduce the morbidity and mortality associated with
cardiovascular disease in patients with T2DM.
There are several factors responsible for this increased risk. Various
authors have suggested that reactive oxygen species (ROS) contribute
to the increased burden of cardiovascular disease in people with
T2DM, due to an increased production of reactive oxygen species thatewYorkHarbor VAHealth Care
land Ltd. This is an open access articlproduce structural changes in lipoproteins that markedly increase
their atherogenic potential.
Vitamin E is known to have an antioxidant property that decreases
ROS levels. In the past, preclinical and observational studies motivated
some cardiologists to prescribe vitamin E for patients with T2DM. Clin-
ical trials did not support the ability of vitamin E supplementation to
provide cardiovascular protection in genetically unselected populations
with T2DM. However, some investigators have suggested that vitamin E
can reduce cardiovascular disease events in subpopulations of patients
with T2DM.
The topic of this review is important because diabetes is a common
condition with high rates of incidence and prevalence. It is estimated
that between 2009 and 2034, the number of diabetic patients in the
United States will increase from 23.7 million to 44.1 million [5]. Also,
if the use of vitamin E is shown to have positive effects in a clearly
identiﬁed group of T2DM patients, the cost associated with care in this
population can be signiﬁcantly reduced.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The objective of this systematic review is to determine whether the
use of vitamin E supplementation is effective in reducing the cardiovas-
cularmortality in T2DMpatients, including any relevant subpopulations.
3. Methods
The studies included in this review were based on the following cri-
terion. The population included individuals with T2DM and acute myo-
cardial infarction with or without T2DM. A study by Milman et al. [10]
further classiﬁed the diabetic population depending on their genotype:
haptoglobin (Hp). The study only included diabetic patientswith theHp
2–2 genotype. This method of genotype classiﬁcation was also present
in Blum et al., Costacou et al., and Koren et al. [1,2,7], which explored al-
ternative medicinal interventions among patients with T2DM, Lee et al.
[8], which focused on females in the Women's Health Study, as well as
the meta-analytic study of Vardi et al. [12]. Genotype classiﬁcation
was also evident in the review articles published by Goldenstein et al.
[4] and Sarmento et al. [11], which shared this similarity with the afore-
mentioned studies, focusing on the subgroup of individuals with the Hp
2–2 genotype. Meanwhile, Farbstein et al. [3] classiﬁed participants,
according to genotype, utilizing the inclusion of DM patients with
both Hp 2–2 and Hp 2–1 genotypes within the analysis.
All studies excluded patientswith uncontrolled hypertension, stroke
within 1 month before enrollment, unwillingness to stop antioxidants
supplements, or known allergy to vitamin E. In addition, the study by
Milman et al. [10] excluded the diabetic population with Hp 1–1 and
Hp 2–1 genotypes; Jaxa-Chamiec et al. [6] excluded death due to non-
cardiac related cause and Marchioli et al. [9] excluded populations
with baseline CHF managed by a multiple drug regimen.
The intervention used in the studies was vitamin E 300 mg/day [9],
600 mg/day [6], and 400 IU/day [1,2,8,10]. This was with the exception
of Koren et al. [7], which implemented a survey approach in obtaining
data related to participants' existing regimen of medication and, there-
fore, was not reliant on the execution of an intervention, as was also the
case with the reviews authored by Goldenstein et al. [4] and Sarmento
et al. [11]
The treatment groups were compared with control groups, who
were given visually matched n-polyunsaturated fatty acid 1 g/day [9],
vitamin C 1200 mg/day [6] and placebo.
The main outcomes measured were mortality related to cardiovas-
cular events, risk of developing CHF, and hospitalization for cardiovas-
cular complication. One other outcome measure was HDL function as
it pertains to the risk for CVD, thereby proving relevant within this
context, based upon its response to vitamin E (or, the lack thereof).
The studies were double blind, randomized, and placebo-controlled
with the exception of the meta-analyses and reviews. In addition,
Costacou et al. [2] and Farbstein et al. [3] employed a crossover design,
supplementing the aforementioned study design characteristics.
The study facilitated by Blum et al. sought to validate the prior ﬁnd-
ings of the ICARE study or Israeli Cardiovascular vitamin E study and the
Heart Outcomes Prevention Evaluation study (HOPE) [1]. Participants
were further characterized as presenting with a diagnosis of DM and
Hpgenotype,whichwas evaluated through gel electrophoresis [1]. Indi-
vidualswith theHp2–2 phenotypewere then randomized and assigned
to either the vitamin E or the placebo group [1].
Established upon the relationship between HDL function and risk of
CVD, Costacou et al. examined the effect of vitamin E on HDL function
compared to placebo. Participants were derived from Allegheny County
diabetes registries and 30 individuals randomly assigned to each of 3
genotype groups (Hp 1–1, Hp 2–1 and Hp 2–2) and administered
daily α-tocopherol or placebo for a period of 8 weeks [2]. This was
followed by a 4-week “washout” period, which then led into the cross-
over in which those given vitamin E were provided with placebo and
vice versa [2].In the research conducted by Farbstein et al., 59 DM participants
were categorized as presenting with either the Hp 2–1 or Hp 2–2 geno-
type. Participants in this double-blind design were administered vita-
min E or a placebo for a 3-month period of duration [3]. The groups
then crossed over and the original vitamin E group then received place-
bo and vice versa for another 3-month study period [3]. HDL functional-
ity wasmeasured at baseline and upon the completion of each 3-month
study period [3].
Patients in the study by Jaxa-Chamiec et al. were given infused and
oral vitamin E and vitamin C together, and the other group in the
study was given infusion of saline placebo [6].
In the study performed byMarchioli et al., the populationwas divid-
ed into four groups who were given vitamin E, n-polyunsaturated fatty
acids, both, or neither, and were followed for 3.5 years [9]. Echocardio-
graphic measurement of left ventricular ejection fraction was deter-
mined and patients developing CHF were deﬁned as “hospitalization
or death for CHF” [9].
The study performed by Milman et al. took place within 47 primary
health care clinics in the Haifa and Western Galilee district of Clalit
Health Services [10]. Hp phenotypingwas performed by electrophoresis
and the diabetic populations with Hp 2–2 were selected. A computer
generated randomization was used to divide study population into
two groups from with one group received vitamin E and another
group received placebo [10].
Koren et al. [7] was a cross-sectional study established upon ques-
tionnaire data retrieved from T2DM patients at Assah Harofeh Medical
Center in Israel. Finally, Goldenstein et al. [4] and Sarmento et al. [11]
employed a meta-analytic and systematic review approach, identifying
the impact of vitamin E on CVD in patients with diabetes.
Key words used in literature searches were vitamin E, antioxidant,
congestive heart failure, myocardial infarction, diabetes mellitus, and
oxidative stress. All articles were published in the English language in
peer-reviewed journals. Articles used in the review were searched and
selected by the author using literature searches like Ovid, Medline,
and Cochrane. Articles were selected based on their relevance and
outcomes. The studies included were conducted in a randomized, con-
trolled fashion in a prospective, intention to treat basis, and dated
after 2004. The statistics utilized in the studieswere p-value, conﬁdence
interval (CI), relative risk reduction (RRR), absolute risk reduction
(ARR) and number needed to treat (NNT).
4. Outcomes measured
The primary outcome measured was incidence of cardiovascular
morbidity and mortality in the study population, supplemented with
HDL function as it relates to CVD. Blum et al. [1] examined myocardial
infarction and cardiovascular death, which also served as endpoints in
Vardi et al. [12], while Costacou et al. [2] examined risk for CVD and car-
diovascular complications. Farbstein et al. [3] evaluated HDL function
and HDL oxidation and inﬂammation markers. Jaxa-Chamiec et al. [6]
measured the primary outcome based on 30-day cardiac mortality in-
hospital or out-hospital. Lee et al. [8] included total mortality and ische-
mic stroke among CVD endpoints. Marchioli et al. [9] measured the risk
of developing congestive heart failure by performing echocardiogram
measurement of the ejection fraction and deﬁned the population devel-
oping CHF during the study as “death or hospitalization due to CHF”. In
the study performed by Milman et al. [10], investigators measured pri-
mary outcome based on a composite of cardiovascular death, nonfatal
myocardial infarction, and stroke. Milman et al. also measured second-
ary outcomes, which included total mortality, hospitalization for con-
gestive heart failure, and coronary revascularization.
5. Results
The results pertaining to the primary outcome were documented as
dichotomous data in Jaxa-Chamiec et al. [6], Marchioli et al. [9], and
Table 1
Demographics and characteristics of included studies.
Characteristics of studies included in a systematic review of the addition of vitamin E in the regimen of myocardial infarction in patients with diabetes mellitus
Study Type #Pts Age (years) Inclusion criteria Exclusion criteria W/D Intervention
Jaxa-Chamiec,
2005 [6]
Randomized,
placebo-controlled
double-blind clinical study
800 50–75 In-hospital or out-hospital
cardiac mortality in patients
with or without diabetes mellitus
Documented non-cardiac cause 0 Vitamin E 600 mg/day;
Vitamin C 1200 mg/day
Marchioli,
2006 [9]
Open label, randomized,
clinical trial
8415 45–70 No diagnosis of heart failure and
an echocardio-graphic
measurement of ejection fraction
(EF) at baseline
Heart failure at baseline; use of
angiotensin-converting enzyme
inhibitors, Beta-blockers, diuretics,
or nitrates for CHF management.
220 Vitamin E 300 mg/day;
n-3 polyunsat-urated
fatty acids 1 g/day
Milman,
2008 [10]
Prospective,
double-blinded
clinical trial
1434 ≥55 ≥55 y/o T2DM and Hp 2–2
genotype
Hp 1–1 and 2–1 genotypes; uncontrolled
hypertension; MI or stroke within
1 month before enrollment;
unwillingness to stop antioxidant
supplements; known allergy to
Vitamin E
136 Vitamin E 400 IU/day;
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tion to treat analysiswith the exception of participantswho did not par-
ticipate till the end of the study or those who were lost to follow-up or
noncompliant.
Blum et al. [1] reported a reduction related to the composite
end point outcomes associated with use of vitamin E in Hp 2–2 DM
patients(odds ratio: 0.58; 95% CI: 0.40–0.86; p = 0.006). Costacou
et al. found that LDL particles increasedwith vitamin E supplementation
in Hp 1 carriers, while decreasing LDL particles in Hp 2 participants.
However, neither was statistically signiﬁcant [2]. Farbstein et al. [3]
found that vitamin E did increase HDL function in Hp 2–2 participants,
while decreasing it in Hp 2–1 individuals with both outcomes present-
ing to a signiﬁcant extent. Lee et al. [8] reported a reduction in totalmor-
tality amongHp 2–2 DM individuals, whowere administered vitamin E.
This ﬁnding was not statistically signiﬁcant (HR 0.922 [0.739–2.600]),
but did replicate the same results formerly realized in the ICARE and
HOPE studies [7].
Jaxa-Chamiec et al. [6] reported cardiovascular mortality of 8% and
22% in the vitamin E and control groups (vitamin C), respectively. This
difference was statistically signiﬁcant (p= 0.036). The absolute risk re-
duction (ARR) was calculated to be 14% and the relative risk reduction
(RRR) was 175%. This study determined that the number needed to
treat (NNT) was 7 patients using the dosage of 600 mg/day (Table 2).
(See Table 1.)
Marchioli et al. [9] reported hospitalization and death due to conges-
tive heart failure of 4.7% and 2.2% in the vitamin E and control groups (n-
polyunsaturated fatty acid), respectively. This differencewas statistical-
ly nonsigniﬁcant (p= 0.18). The treatment with vitamin E in this study
was associated with increased risk of developing CHF. The absolute risk
reduction (ARR) was calculated to be 2.5% and the relative risk reduc-
tion (RRR) was 53%. This study determined that number needed to
treat (NNT) was 40 patients using the dosage of 300 mg/day (Table 2).
Milman et al. [10] reported cardiovascular death, nonfatal myocardi-
al infarction, and stroke of 1.6% and 4.6% in the vitamin E and control
groups, respectively. This difference was statistically signiﬁcant
(p = 0.003). The absolute risk reduction (ARR) was calculated to be
3% and the relative risk reduction (RRR) was 187.5%. This study deter-
mined that the number needed to treat (NNT) was 33 patients using
the dosage of 400 IU/day (Table 2).Table 2
Efﬁcacy of vitamin E in cardiovascular mortality.
Study Vitamin E group (CER) Control group (EER)
Jaxa-Chamiec [6] 8% 22%
Marchioli [9] 4.7% 2.2%
Milman [10] 1.6% 4.6%
CI = Conﬁdence Interval, RRR = Relative Risk Reduction, ARR = Absolute Risk Reduction, NN
a Since the outcomemeasured was incidence and severity of cardiovascular disease, the neg
one fewer incidence of cardiovascular complication than in the group of participants taking plaIn the meta-analytic study facilitated by Vardi et al. [12], the odds
ratio for a CVD endpoint in Hp 2–2 genotype participants was favorable
(.66) to the individuals treated with the vitamin E supplement (95% CI
0.48 to 0.9). Finally, Koren et al. [7] identiﬁed a marginal impact of vita-
min E among 111 patients, while the meta-analytic reviews facilitated
by Goldenstein et al. [4] and Sarmento et al. [11] both reported the ben-
eﬁt of vitamin E among the subgroup of Hp 2–2 DM individuals.
As seen in Table 2, the Relative Risk Reduction (RRR) is high in both
the Jaxa-Chamiec andMilman studieswith 175% and 187.5% respective-
ly; however, theMarchioli studydid not showa similar reduction in car-
diac mortality, with a RRR of 53%. It is also was reﬂected in number
needed to treat (NNT) for Marchioli study, which was higher compared
with the other two studies.
If we compare the doses of vitamin E used in the three studies, it ap-
pears that Jaxa-Chamiec utilized a dose of 600mg/day, which is approx-
imately ﬁve to six times more effective with a NNT value of 7 compared
with a dose of 300 mg/day and 400 IU/day used by Marchioli and
Milman with a NNT value of 40 and 33, respectively. However, there
are no data in the study that compare the dosage of vitamin E.
Secondary end points measured in the study by Milman et al. [10]
did not show a signiﬁcant difference in the group treated with vitamin
E compared to the placebo. The results for the secondary end points
are listed in Table 3.
The studies chosen for this review had certain limitations. The stud-
ies did not include all the participants in the results, because somewere
excluded from the study. In the study byMilman et al. [10], 136 subjects
were not included in the results: two were lost to follow up; seven due
to their physician's advice; eleven due to side effects, and 116were non-
compliant based on telephone interviews. Also, in this study, no attempt
wasmade to optimize or manage the medication prescribed by the pri-
mary care physician. A limitation of the Jaxa-Chamiec et al. [6] study is
the retrospective mode of analysis performed on the diabetic patient
subgroup and the secondary analysis (effects of antioxidant vitamins
on patients older than 70 years, anterior myocardial infarction, and
symptoms of AMI for N12) did not reach signiﬁcance and hence failed
to support the primary hypothesis of the study.
All the clinical trials have failed to test the basic foundation underly-
ing the hypothesis, which is the capacity of the antioxidant to reduce
oxidative stress. None of the studies measured the oxidative states inp-value 95% CI RRR ARR NNT
0.036 0.51 to 1.85 175% 14% 7
0.18 0.92 to 1.56 −53% −2.5% −40a
0.003 0.16 to 0.70 187.5% 3% 33
T = Number Needed to Treat.
ative value for NNT indicates that for every 40 participants who took Vitamin E, there was
cebo.
Table 3
Secondary end point analysis of treatment outcomes.
End points Vitamin E Placebo p-value RRR ARR NNT
Revascularization 11 (1.5%) 18 (2.5%) 0.17 66% 1% 1
Congestive heart failure 8 (1.1%) 8 (1.1%) 0.96 0 0 0
Total mortality 11 (1.5%) 12 (1.7%) 0.77 13% 0.2% 5
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idant supplementation without knowing the initial oxidative stress a
person is experiencing. It is hard to show the effect of a substance with-
out determiningwhat it is actually having the effect on in the ﬁrst place.
6. Discussion
Oxidative modiﬁcation by reactive oxidative species (ROS) of low-
density lipoprotein is an important step in the development and pro-
gression of atherosclerotic plaque. ROS are found in high quantity in
the hyperglycemic state of diabetic patients. Increased oxidative stress
has been linked to impaired endothelial function [6]. Vitamin E has
antioxidant properties that help reduce ROS formation, which inhibit
the formation of atherosclerotic plaque. Reduction in the formation of
atherosclerotic and endothelial damage can reduce cardiovascular dam-
age in the diabetic population.
According to the study of Marchioli et al., there is a signiﬁcant rela-
tionship between plasma oxidized low-density lipoprotein and severity,
aswell asworsening ejection fraction and higher level of neurohormon-
al activation in patients with CHF [9]. However, its effect was not repro-
ducible in the study,which concluded that vitamin E leads to depression
of myocardial function and hospitalization and death in CHF. Hence,
vitamin E did not show a beneﬁcial role in prevention of congestive
heart failure after a myocardial infarction in the context of this study.
However, the study on a diabetic population with the Hp 2–2 geno-
type by Jaxa-Chamiec et al. [6] showed cardiovascular beneﬁts from vi-
tamin E supplementation. It was concluded that vitamin E reduced
cardiovascular death and AMI in the speciﬁc population with the Hp
2–2 genotype. This was a ﬁnding that was reafﬁrmed in many of the
studies, including that of Blum et al. [1], reporting that vitamin E sup-
plementation produced “…an overall reduction of over 40% in the
combined end point of stroke,MI and CVDdeath”within the Hp 2–2 ge-
notype group. Similar ﬁndings were reported in the meta-analyses and
reviews facilitated by Goldenstein et al. [4] and Sarmento et al. [11], re-
vealing a consensus in favor of vitamin E and its clinical applicability in
Hp 2–2 DM patients for reducing and/or preventing risks associated
with CVD. Similar assertions were set forth in Vardi et al. [12] and
Koren et al. [7], although in the latter the effect was marginal and fell
short of the criteria for statistical signiﬁcance.
Both the studies of Costacou et al. and that of Farbstein et al. focused
on HDL function as an outcome, offering a potential explanation for one
of the underlyingmechanisms that contribute to the beneﬁcial effect of
vitamin E on CVD outcomes in DMpatients. As a result, this research not
only further validates the aforementioned studies, lending credibility to
the positive ﬁndings associated with vitamin E, but each also reinforces
the positive clinical impact as is applicable to the Hp 2–2 subgroup of
patients, while conversely illustrating the negative impact on the Hp
2–1 subgroup [2,3]. Finally, Lee et al. [8] demonstrated a reduction in
total mortality for the Hp 2–2 DM subgroup, asserting a broader overall
effect realized as a function of vitamin E, which served to reinforce the
prior ﬁndings set forth in the ICARE and HOPE research studies.7. Conclusion
According to Marchioli et al., vitamin E has a deleterious effect on
cardiovascular outcomes, particularly late-onset heart failure [9]. The
study showed a statistically nonsigniﬁcant increased risk of developing
CHF due to depression of left ventricular function with addition of vita-
min E supplementation to their therapy. According to Jaxa-Chamiec
et al. [6], the antioxidative property of vitamin E signiﬁcantly reduces
30-day mortality in diabetic patients with recent MI, but the secondary
analysis in a trial failed to support its primary hypothesis and the valid-
ity of the trial is questionable. However, according to Blum et al.,
Costacou et al., Farbstein et al., Goldenstein et al., and Milman et al.
[1–4,10], vitamin E provides cardiovascular beneﬁt to diabetic individ-
uals with the Hp 2–2 genotype. Vitamin E supplementation in this pop-
ulation was shown to reduce cardiovascular death and myocardial
infarction.
Hence, it can be concluded that vitamin E is effective in diabetic
patients with the Hp 2–2 genotype and can have an adverse effect in
the non-diabetic population or other Hp genotype subgroups. Future
research should be implemented for the purpose of replicating the ﬁnd-
ings realized here, pertaining to the effect of vitamin E in Hp 2–2 geno-
type diabetic patients. In doing so, further clariﬁcation will be achieved,
regarding the use of vitamin E in speciﬁc diabetic populations. In a clin-
ical capacity, the use of genotyping coupled with the appropriate use of
vitamin E in these populationsmay reduce the cost of treatment, aswell
as minimize cardiovascular complications in diabetic populations.
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